BY MARKETWIRE
-
Eli Lilly failed to meet sales expectations in Q3
Eli Lilly has actually reported even worse than anticipated sales numbers for weight management medicine Zepbound and kind 2 diabetic issues medicine Mounjaro.
-
Jefferies sees increased potential for Lundbeck share
Nonetheless, the economic team additionally mentions that Lundbeck’s medicine prospects in the pipe are related to high threat.
-
Olympus CEO pushed out after allegation he bought illegal drugs
The German chief executive officer invested much less than 2 years accountable of the Japanese medtech firm.
-
Analysts warn Novo Nordisk’s next sales figures could disappoint
Banks including JPMorgan, Barclays and Bank of America have lowered their expectations for Novo Nordisk’s sales in the third quarter of the year.
-
Novo Nordisk Pharmatech launches new enzyme for drug production
Trypsin merchandise like Trypsinnex are utilized in bioproduction processes similar to cell dissociation, virus activation and insulin manufacturing
-
WSA to continue supplying hearing aids to US chain Costco
Although the grocery store chain prepares to market the rival’s listening devices, WSA remains to provide Costco.
-
Novo Nordisk’s production expansion is going too slowly, bank claims
Novo Nordisk is presently experiencing traffic jams in the supply chain, and it’s the business’s very own mistake, according to a significant Austrian monetary companie…
-
Analysts: Zealand Pharma and Sanofi could be a perfect match
Zealand Pharma can be the optimal companion for Sanofi to get to the weight problems market, according to experts from Intron Wellness.
-
Genmab to receive more in royalties as Novartis exceeds expectations
Novartis has actually defeated its sales assumptions for sclerosis medication Kesimpta, which was initially established by Genmab.
-
Bavarian Nordic to expand smallpox vaccine indication to toddlers
The Danish injection firm has actually released a brand-new medical research study in youngsters.
